Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment

被引:18
|
作者
Yamanashi, Yuji [1 ]
Tezuka, Tohru [1 ]
Yokoyama, Kazumasa [1 ]
机构
[1] Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Genet,Minato Ku, Tokyo 1088639, Japan
来源
JOURNAL OF BIOCHEMISTRY | 2012年 / 151卷 / 04期
基金
日本学术振兴会;
关键词
cancer; cytohesin; Dok-7; myasthenia; neuromuscular junction; NEUROMUSCULAR SYNAPSE FORMATION; GROWTH-FACTOR RECEPTOR; ACETYLCHOLINE-RECEPTOR; EGF RECEPTOR; MUSK; MUSCLE; DOK-7; MYASTHENIA; JUNCTION; ROLES;
D O I
10.1093/jb/mvs013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It is widely accepted that receptor protein-tyrosine kinases (RTKs) are activated upon dimerization by binding to their extracellular ligands. However, EGF receptor (EGFR) dimerization per se does not require ligand binding. Instead, its cytoplasmic kinase domains have to form characteristic head-to-tail asymmetric dimers to become active, where one 'activator' domain activates the other 'receiver' domain. The non-catalytic, cytoplasmic regions of RTKs, namely the juxtamembrane and carboxy terminal portions, also regulate kinase activity. For instance, the juxtamembrane region of the RTK MuSK inhibits the kinase domain probably together with a cellular factor(s). These findings suggest that RTKs could be activated by cytoplasmic proteins. Indeed, Dok-7 and cytohesin have recently been identified as such activators of MuSK and EGFR, respectively. Given that failure of Dok-7 signaling causes myasthenia, and inhibition of cytohesin signaling reduces the proliferation of EGFR-dependent cancer cells, cytoplasmic activators of RTKs may provide new therapeutic targets.
引用
收藏
页码:353 / 359
页数:7
相关论文
共 50 条
  • [31] CINNAMAMIDE ANALOGS AS INHIBITORS OF PROTEIN-TYROSINE KINASES
    BUZZETTI, F
    BRASCA, MG
    CRUGNOLA, A
    FUSTINONI, S
    LONGO, A
    PENCO, S
    ZONCA, PD
    COMOGLIO, PM
    FARMACO, 1993, 48 (05): : 615 - 636
  • [32] PROTEIN-TYROSINE KINASES, WITH EMPHASIS ON THE SRC FAMILY
    COURTNEIDGE, SA
    SEMINARS IN CANCER BIOLOGY, 1994, 5 (04) : 239 - 246
  • [33] Protein-tyrosine kinases and phosphatases in cell signaling
    Hunter, T
    Bilwes, A
    Broome, M
    denHertog, J
    Noel, J
    Schlaepfer, D
    FASEB JOURNAL, 1996, 10 (06): : P1 - P1
  • [34] A PROTEIN-TYROSINE PHOSPHATASE WITH SEQUENCE SIMILARITY TO THE SH2 DOMAIN OF THE PROTEIN-TYROSINE KINASES
    SHEN, SH
    BASTIEN, L
    POSNER, BI
    CHRETIEN, P
    NATURE, 1991, 352 (6337) : 736 - 739
  • [35] THE SYNTHESIS OF PYRANOACRIDINONE INHIBITORS OF PROTEIN-TYROSINE KINASES
    GROUNDWATER, PW
    SOLOMONS, KRH
    JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1994, (02): : 173 - 177
  • [36] EEK AND ERK, NEW MEMBERS OF THE EPH SUBCLASS OF RECEPTOR PROTEIN-TYROSINE KINASES
    CHAN, J
    WATT, VM
    ONCOGENE, 1991, 6 (06) : 1057 - 1061
  • [39] DIFFERENTIAL EXPRESSION OF ZAP-70 AND SYK PROTEIN-TYROSINE KINASES, AND THE ROLE OF THIS FAMILY OF PROTEIN-TYROSINE KINASES IN TCR SIGNALING
    CHAN, AC
    VANOERS, NSC
    TRAN, A
    TURKA, L
    LAW, CL
    RYAN, JC
    CLARK, EA
    WEISS, A
    JOURNAL OF IMMUNOLOGY, 1994, 152 (10): : 4758 - 4766
  • [40] Demonstration of FPS/FES and FER cytoplasmic nonreceptor protein-tyrosine kinases in platelets and their involvement in thrombin and thrombopoietin receptor signaling.
    Senis, YA
    Zirngibl, RA
    Peterson, NT
    Samis, JA
    Greer, PA
    BLOOD, 2000, 96 (11) : 247A - 247A